BioMarin Pharmaceutical reported $333.64M in Selling and Administration Expenses for its fiscal quarter ending in September of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.88M 1.69M Sep/2026
Agios Pharmaceuticals USD 51.55M 13.09M Jun/2026
Alnylam Pharmaceuticals USD 342M 5.92M Sep/2026
Amgen USD 1.68B 40M Sep/2026
Bayer EUR 4.02B 53M Sep/2026
Biogen USD 752M 42.3M Sep/2026
BioMarin Pharmaceutical USD 333.64M 61.91M Sep/2026
Gilead Sciences USD 1.52B 70M Jun/2026
Incyte USD 364.27M 12.54M Sep/2026
Insmed USD 253.03M 5.56M Sep/2026
Ionis Pharmaceuticals USD 154M 23.92M Sep/2026
Moderna USD 282M 66M Sep/2026
Neurocrine Biosciences USD 366.3M 16.8M Sep/2026
PTC Therapeutics USD 80.63M 6.74M Jun/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.63B 140M Jun/2026
Sarepta Therapeutics USD 118.61M 11.01M Sep/2026
Ultragenyx Pharmaceutical USD 97M 9M Sep/2026
United Therapeutics USD 184.1M 22.6M Sep/2026
Vertex Pharmaceuticals USD 556.3M 25.9M Sep/2026